Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Cool Planet Energy to Further Develop Second Generation Biofuel Capability

Published: Thursday, October 31, 2013
Last Updated: Thursday, October 31, 2013
Bookmark and Share
Cool Planet Energy will further develop its capabilities in second generation biofuels following $19.4m of new funding, in addition to the $29.9m investment received in June this year.

Cool Planet Energy currently develop cellulosic “drop-in” biofuels for use in motor vehicles and aeroplanes in the United States. These “second generation” biofuels are made from non-food sources of biomass like crop waste or forestry by-products, rather than relying on conventional food crops like corn or sugar cane.

The new investment will fund engineering design for the first of three commercial facilities, with the hope of producing 10 million gallons of high-octane cellulosic gasoline by the end of 2014. The new facility will also allow for the production of biochar, which can be returned to soil to improve water retention, crop productivity and plant health. This process is ‘carbon negative’, reversing the consequences of fossil fuels by removing up to 150 per cent of CO2 for every gallon used.

Second-generation fuels have the advantage of utilising biomass which would not otherwise have been used for human consumption. Crops like switchgrass or miscanthus can potentially be grown on lands that are not suitable for growing food crops, needing little or no fertilizers or irrigation, reducing nutrient and water requirements. They also put less pressure on worldwide food prices, as seen with corn-ethanol production in the United States. 

So far, cellulosic technology has struggled to reach commercial viability, with costs of production relatively high in comparison to corn-based ethanol. However, a recent report by Bloomberg’s New Energy Finance (BNEF) found that second generation biofuels should become cost-competitive fuel solutions by 2016, with the costs of enzymes and processes associated with their production falling.  

Cool Planet Energy’s technology is clearly providing investors with confidence about its long term viability, attracting some of the industry’s biggest names, including investors from Hong Kong, Singapore, the United Arab Emirates and Mexico. Cool Planet is hoping to extend its distribution network all over the world, developing partnerships with key players in international markets:

“While equity markets remain closed to most biofuel businesses, investors are seeing a differentiated opportunity in Cool Planet. Our drop-in cellulosic gasoline and biochar technology has global potential,” said Cool Planet CEO, Howard Janzen. 

“A strong proof point for this potential is the impressive group of international investors who have participated in our equity raise, positioning the company for long-term growth globally,” he added. 

As investment in second generation fuels grows, producers like Cool Planet Energy will see their relative costs of production fall, which will allow further investment in productive capacity. Cellulosic fuels will then likely rival traditional biofuels like ethanol as a cost-effective source of renewable fuel. 

Robert Potts is the managing director of RPM Fuels, suppliers of tanks and equipment to the fuelling industry; check out his latest updates on Google+

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos